Abstract
Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Letters in Drug Design & Discovery
Title: Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy
Volume: 2 Issue: 7
Author(s): Marco L. Rossi, Dennis Zavalloni, Guido Belli and Patrizia Presbitero
Affiliation:
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Abstract: Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Export Options
About this article
Cite this article as:
Rossi L. Marco, Zavalloni Dennis, Belli Guido and Presbitero Patrizia, Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy, Letters in Drug Design & Discovery 2005; 2 (7) . https://dx.doi.org/10.2174/157018005774479168
DOI https://dx.doi.org/10.2174/157018005774479168 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters Non-Hormonal Replacement Therapy Regimens: Do they have an Effect on Cardiovascular Risk?
Current Vascular Pharmacology Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Relevance of Postprandial Lipemia in Metabolic Syndrome
Current Vascular Pharmacology Modulatory Role of Nitric Oxide/cGMP System in Endothelin-1-Induced Signaling Responses in Vascular Smooth Muscle Cells
Current Cardiology Reviews Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery
Mini-Reviews in Medicinal Chemistry Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives
Current Topics in Medicinal Chemistry Renin Inhibition as a New Strategy to Combat Cardiovascular Disease
Current Hypertension Reviews The Use of Statins in Hematopoietic Stem Cell Transplantation
Current Stem Cell Research & Therapy Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews Depression Related Pathophysiologies Relevant in Heart Disease: Insights into the Mechanism Based on Pharmacological Treatments
Current Cardiology Reviews Tissue Factor and Atherothrombosis
Current Pharmaceutical Design Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Physiological Insights Derived from Mathematical Models of Respiration
Current Respiratory Medicine Reviews L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in more Anti-Inflammatory HDL in Mice
Drug Metabolism Letters Heart Failure in South America
Current Cardiology Reviews The Expression of Activity-Dependent Neuroprotective Protein (ADNP) is Regulated by Brain Damage and Treatment of Mice with the ADNP Derived Peptide, NAP, Reduces the Severity of Traumatic Head Injury
Current Alzheimer Research Transdermal Drug Delivery of Labetolol Hydrochloride: System Development, In Vitro; Ex Vivo and In Vivo Characterization
Current Drug Delivery